New hope for early breast cancer: 3-Drug combo trial seeks to shrink tumors before surgery
NCT ID NCT06318897
Summary
This study is testing whether a combination of three drugs (pembrolizumab, carboplatin, and paclitaxel) can effectively shrink early-stage triple-negative breast cancer tumors before surgery. The goal is to see if this approach can help patients avoid more intensive chemotherapy while still achieving good results. Researchers will enroll 28 adults with small tumors that haven't spread to lymph nodes to test both effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.